Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -34.55% is 61% below its 5-year average of -21.40%, near the low end of its 5-year range (-34.55%–-12.63%).
15.11% below its 12-month average of -30.02%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.85%.
RETURN ON ASSETS (ROA)
-34.55%
RETURN ON ASSETS (ROA) AVG TTM
-30.02%
RETURN ON ASSETS (ROA) AVG 3Y
-24.36%
RETURN ON ASSETS (ROA) AVG 5Y
-21.40%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-15.11%
CURRENT VS 3Y AVG
-41.86%
CURRENT VS 5Y AVG
-61.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
-10.14%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$240.26M
Return on Assets (ROA)
-34.55%
TTM Avg
-30.02%
3Y Avg
-24.36%
5Y Avg
-21.40%
Market Cap
$242.31M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$242.27M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$242.23M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$242.02M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$245.55M
Return on Assets (ROA)
29.16%
TTM Avg
-1.71%
3Y Avg
-34.07%
5Y Avg
-33.80%
Market Cap
$245.30M
Return on Assets (ROA)
-50.89%
TTM Avg
-41.00%
3Y Avg
-37.00%
5Y Avg
-42.85%
Market Cap
$238.90M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$238.48M
Return on Assets (ROA)
-1.57%
TTM Avg
17.43%
3Y Avg
19.75%
5Y Avg
24.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $240.26M | -34.55% | -30.02% | -24.36% | -21.40% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | -14.72% | -16.00% | -18.82% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.27M | -244.25% | -369.36% | -230.97% | -157.86% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.23M | -114.79% | -67.19% | -63.94% | -45.91% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | -187.80% | -213.40% | -188.65% | -151.14% |
| Q32 Bio Inc. (QTTB)vs › | $245.55M | 29.16% | -1.71% | -34.07% | -33.80% |
| Quantum-Si incorporated (QSI)vs › | $245.30M | -50.89% | -41.00% | -37.00% | -42.85% |
| Invivyd, Inc. (IVVD)vs › | $238.90M | -49.04% | -75.08% | -74.95% | -71.96% |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | -1.57% | 17.43% | 19.75% | 24.82% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.60M | -8.48% | -16.43% | -20.20% | -32.31% |
ROA
-34.5%
ROE
-43.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.87% |
| 2024-12-31 | -29.16% |
| 2023-12-31 | -20.84% |
| 2022-12-31 | -16.55% |
| 2021-12-31 | -12.63% |
| 2020-12-31 | -18.37% |
| 2019-12-31 | -51.87% |
| 2018-12-31 | 429.71% |
